Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19.

Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19.

Publication date: Dec 18, 2024

In the filed of antiviral therapy, effective therapeutic concentration is beneficial to shorten the recovery time of patients and reduce the transmission rate. The aim of this study is to retrospectively analyze the factors that lead to the drug concentration of Nirmatrelvir /Ritonavir (NMV/RTV) not reaching the standard. In this study, the NMV/RTV drug concentration(Cnmv/rtv) data (n = 114) of COVID-19 patients over 18 years old were collected from May 2022 to July 2022, and the results of the patients were retrospectively compared. According to the analysis of the early study of NMV/RTV, combined with the research results at home and abroad, according to whether the measured drug concentration > 987 ng/ml, the patients were divided into target group and non-target group,The non-target group was defined as not reaching the trough concentration level. Serum NMV/RTV concentration in adult patients was correlated with prognostic nutritional index [PNI, (P 

Open Access PDF

Concepts Keywords
Covid Adult
July Aged
Nutritional Antiviral Agents
Therapy Antiviral Agents
COVID-19
COVID-19 Drug Treatment
CrCl
Drug Combinations
Drug Combinations
Female
Humans
Lopinavir
Lopinavir
Male
Middle Aged
Nirmatrelvir/Ritonavir
PNI
Retrospective Studies
Ritonavir
Ritonavir
SARS-CoV-2
Therapeutic drug monitoring
Trough concentration

Semantics

Type Source Name
drug DRUGBANK Ritonavir
disease MESH COVID-19
disease MESH Infectious Diseases
pathway REACTOME Reproduction
drug DRUGBANK Creatinine
disease MESH nutritional status
disease MESH infection
disease IDO pathogen
disease IDO host
pathway KEGG Viral replication
drug DRUGBANK Favipiravir
disease MESH critically ill
disease IDO replication
disease IDO process
disease MESH death
pathway REACTOME Metabolism
drug DRUGBANK Tacrolimus
drug DRUGBANK Voriconazole
drug DRUGBANK Ciclosporin
disease MESH tic
disease IDO blood
drug DRUGBANK Coenzyme M
drug DRUGBANK Methionine
drug DRUGBANK Saquinavir
disease IDO nucleic acid
disease MESH cardiovascular disease
disease MESH cancer
drug DRUGBANK Prothrombin
disease MESH Diabetes mellitus
disease MESH Pulmonary diseases
disease IDO symptom
disease MESH treatment failure
disease MESH viral load
drug DRUGBANK Urea
drug DRUGBANK Nitrogen
disease IDO protein
drug DRUGBANK Nesiritide
disease MESH liver disease
drug DRUGBANK Human Serum Albumin
disease MESH malnutrition
pathway REACTOME Immune System
disease IDO susceptibility
drug DRUGBANK Indoleacetic acid
disease MESH drug interactions
drug DRUGBANK Digoxin
disease MESH fungal infections
disease MESH emergency
disease MESH morbidity
disease MESH Allergy
disease MESH inflammation
drug DRUGBANK Isosorbide Mononitrate
drug DRUGBANK Lopinavir

Original Article

(Visited 1 times, 1 visits today)